Variant analysis and PGT-M of OTC gene in a Chinese family with ornithine carbamoyltransferase deficiency.
Humans
Ornithine Carbamoyltransferase Deficiency Disease
/ genetics
Ornithine Carbamoyltransferase
/ genetics
Female
Mutation, Missense
Pregnancy
Retrospective Studies
Male
Pedigree
China
Adult
Genetic Testing
/ methods
Prenatal Diagnosis
/ methods
Asian People
/ genetics
Infant, Newborn
East Asian People
OTC
PGT-M
Prenatal diagnosis
Variant
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
22 Jul 2024
22 Jul 2024
Historique:
received:
09
02
2024
accepted:
12
07
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
22
7
2024
Statut:
epublish
Résumé
Ornithine carbamoyltransferase deficiency (OTCD) is a kind of X-linked metabolic disease caused by a deficiency in ornithine transcarbamylase leading to urea cycle disorders. The main reason is that the OTC gene variants lead to the loss or decrease of OTC enzyme function, which hinders the ammonia conversion to urea, resulting in hyperammonemia and severe neurological dysfunction. Here, we studied one Chinese family of three generations who consecutively gave birth to two babies with OTCD. This study aims to explore the pathogenicity of two missense variants in the OTC gene and investigate the application of preimplantation genetic testing for monogenic (PGT-M) for a family troubled by Ornithine carbamoyltransferase deficiency (OTCD). The retrospective method was used to classify the pathogenicity of two missense variants in the OTC gene in a family tortured by OTCD. Sanger sequencing was used to validate the variants in the OTC gene, and then the pathogenicity of variants was confirmed through family analysis and bioinformatics software. We used PGT-M to target the OTC gene and select a suitable embryo for transplantation. Prenatal diagnosis was recommended to confirm previous results using Sanger sequencing and karyotyping at an appropriate gestational stage. Tandem mass spectrometry (MS-MS) and gas chromatography-mass spectrometry (GC-MS) were used to detect fetal metabolism after birth. The number of the study cohort is ChiCTR2100053616. Two missense variants, c.959G > C (p.Arg320Pro) and c.634G > A (p.Gly212Arg), were validated in the OTC gene in this family. According to the ACMG genetic variation classification criteria, the missense variant c.959G > C can be considered as "pathogenic", and the missense variant c.634G > A can be regarded as "likely benign." PGT-M identified a female embryo carrying the heterozygous variant c.959G > C (p.Arg320Pro), which was selected for transplantation. Prenatal diagnosis revealed the same variant in the fetus, and continued pregnancy was recommended. A female baby was born, and her blood amino acid testing and urine organic acid testing were regular. Follow-up was conducted after six months and indicated the girl was healthy. Our research first validated the segregation of both c.959G > C and c.634G > A variants in the OTC gene in a Chinese OTCD family. Then, we classified variant c.959G > C as "pathogenic" and variant c.634G > A as "likely benign", providing corresponding theoretical support for genetic counseling and fertility guidance in this family. PGT-M and prenatal diagnosis were recommended to help the couple receive a female baby successfully with a six-month follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
Ornithine carbamoyltransferase deficiency (OTCD) is a kind of X-linked metabolic disease caused by a deficiency in ornithine transcarbamylase leading to urea cycle disorders. The main reason is that the OTC gene variants lead to the loss or decrease of OTC enzyme function, which hinders the ammonia conversion to urea, resulting in hyperammonemia and severe neurological dysfunction. Here, we studied one Chinese family of three generations who consecutively gave birth to two babies with OTCD. This study aims to explore the pathogenicity of two missense variants in the OTC gene and investigate the application of preimplantation genetic testing for monogenic (PGT-M) for a family troubled by Ornithine carbamoyltransferase deficiency (OTCD).
METHODS
METHODS
The retrospective method was used to classify the pathogenicity of two missense variants in the OTC gene in a family tortured by OTCD. Sanger sequencing was used to validate the variants in the OTC gene, and then the pathogenicity of variants was confirmed through family analysis and bioinformatics software. We used PGT-M to target the OTC gene and select a suitable embryo for transplantation. Prenatal diagnosis was recommended to confirm previous results using Sanger sequencing and karyotyping at an appropriate gestational stage. Tandem mass spectrometry (MS-MS) and gas chromatography-mass spectrometry (GC-MS) were used to detect fetal metabolism after birth. The number of the study cohort is ChiCTR2100053616.
RESULTS
RESULTS
Two missense variants, c.959G > C (p.Arg320Pro) and c.634G > A (p.Gly212Arg), were validated in the OTC gene in this family. According to the ACMG genetic variation classification criteria, the missense variant c.959G > C can be considered as "pathogenic", and the missense variant c.634G > A can be regarded as "likely benign." PGT-M identified a female embryo carrying the heterozygous variant c.959G > C (p.Arg320Pro), which was selected for transplantation. Prenatal diagnosis revealed the same variant in the fetus, and continued pregnancy was recommended. A female baby was born, and her blood amino acid testing and urine organic acid testing were regular. Follow-up was conducted after six months and indicated the girl was healthy.
CONCLUSION
CONCLUSIONS
Our research first validated the segregation of both c.959G > C and c.634G > A variants in the OTC gene in a Chinese OTCD family. Then, we classified variant c.959G > C as "pathogenic" and variant c.634G > A as "likely benign", providing corresponding theoretical support for genetic counseling and fertility guidance in this family. PGT-M and prenatal diagnosis were recommended to help the couple receive a female baby successfully with a six-month follow-up.
Identifiants
pubmed: 39039447
doi: 10.1186/s12884-024-06696-5
pii: 10.1186/s12884-024-06696-5
doi:
Substances chimiques
Ornithine Carbamoyltransferase
EC 2.1.3.3
OTC protein, human
EC 2.1.3.3
Types de publication
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
491Subventions
Organisme : the Major Science and Technology Program of Hainan Province
ID : ZDKJ2021037
Organisme : Hainan Province Science and Technology Special Fund
ID : ZDYF2020117, ZDYF2022SHFZ312
Organisme : Hainan Province Science and Technology Project
ID : LCXY202102, LCYX202203, LCYX202301
Informations de copyright
© 2024. The Author(s).
Références
Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy [J]. Adv Pediatr. 1996;43:127–70.
doi: 10.1016/S0065-3101(24)00072-0
pubmed: 8794176
Caldovie L, Abdikarim I, Narain S, et al. Genotype-pheno-type corrdations in arnithine transcarhamylase deficieney:Amutation update [J]. J Genet Gencmics. 2015;42(5):181–94.
doi: 10.1016/j.jgg.2015.04.003
Prasun P, Alinok D, Misra VK. Ornithine transcarbamylase deficiency presenting with aute reversible corial blind-ness [J]. J Child Neurol. 2015;30(6):782–5.
doi: 10.1177/0883073814535490
pubmed: 24850570
Lee JH, Kim GH, Yoo HW, et al. OTC gene in ornithine-transcarbamylase deficieney:dinical course and mutational spectrum in seven Korean patient [J]. Pediatr Neurol. 2014;51(3):354–9.
doi: 10.1016/j.pediatrneurol.2014.03.029
pubmed: 25011434
POSSET R, BOY GARBADE. Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders-A successful strategy for clinical research of rare diseases [J]. J Inherit Metab Dis. 2019;42(1):93–106.
doi: 10.1002/jimd.12031
pubmed: 30740724
pmcid: 7329920
BURGARD P, KOLKER S, HAEGE G, et al. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders-review and meta-analysis of observational studies published over more than 35 years [J]. J Inherit Metab Dis. 2016;39(2):219–29.
doi: 10.1007/s10545-015-9901-1
pubmed: 26634836
NASSOGNE MC, HERON B, TOUATI G, et al. Urea cycle defects: management and outcome [J]. J Inherit Metab Dis. 2005;28(3):407–14.
doi: 10.1007/s10545-005-0303-7
pubmed: 15868473
TUCHMAN M, LEE B, LICHTER-KONECKI U et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States [J]. Mol Genet Metab 2008,94(4): 397–402.
Horwich AL, Fenton WA, WilliamsKR, et al. Structure and expression of a complementary DNA for the nuclear coded precursor of human mitochondrial ornithine transcarbamylase[J]. Science. 1984;224(4653):1068–74.
doi: 10.1126/science.6372096
pubmed: 6372096
BRAISSANT O. Current concepts in the pathogenesis of urea cycle disorders [J]. Mol Genet Metab. 2010;100(Suppl 1):S3–12.
doi: 10.1016/j.ymgme.2010.02.010
pubmed: 20227314
Jang YJ, LaBella AL, Feeney TP, et al. Disease-causing mutations in the promoter and enhancer of the ornithine transcarbamylase gene [J]. Hum Mutat. 2018;39(4):527–36.
doi: 10.1002/humu.23394
pubmed: 29282796
pmcid: 7388160
ChoiDE, Lee KW, ShinYT, et al. Hyperammonemia in a patient with late onset ornithine carbamoyltransferase deficiency [J]. JKorean MedSci. 2012;27(5):556–69.
Kim GH, ChoiJH, Lee HH. Identification of novelmutations in the human ornithine transcarbamylase (OTC) gene of Korean patients with OTC deficiency and transient expression of the mutant proteins invitro [J]. Hum Mutat. 2006;27(11):1159.
doi: 10.1002/humu.9465
pubmed: 17041896
LICHTER-KONECKI U CALDOVICL, MORIZONO H et al. Ornithine transcarbamylase deficiency [A]// ADAM M P, ARDINGER H H, PAGON R A, Gene reviews, Seattle (WA): University of Washington, 1993.
MORRIS S M J R. Regulation of enzymes of the urea cycle and arginine metabolism [J]. Annu Rev Nutr. 2002;22:87–105.
doi: 10.1146/annurev.nutr.22.110801.140547
HABERLE J, BURLINA A, CHAKRAPANI A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders:first revision [J]. J Inherit Metab Dis. 2019;42(6):1192–230.
doi: 10.1002/jimd.12100
pubmed: 30982989
Ottolenghi SG-LC, Reyal F, et al. OTC deficiency in females: phenotype-genotype correlation based on a 130-family cohort [J]. J Inherit Metab Dis. 2021;44(5):1235–47.
doi: 10.1002/jimd.12404
pubmed: 34014569
Handyside 1 AH, Kontogianni EH, Hardy K, Winston RM. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification [J]. Nature. 1990;344(6268):768–70.
Fridman H, Yntema HG, Mägi R, et al. The landscape of autosomalrecessive pathogenic variants in European populations reveals phenotype-specific effects [J]. Am J Hum Genet. 2021;108(4):608–19.
doi: 10.1016/j.ajhg.2021.03.004
pubmed: 33740458
pmcid: 8059335
Treff NR, Eccles J, Lello L, et al. Utility and first clinical application of screening embryos for polygenic disease risk reduction [J]. Front Endocrinol. 2019;10:845.
doi: 10.3389/fendo.2019.00845
Manish Banker P, Arora, et al. Prevalence of structural birth defects in IVF-ICSI pregnancies resulting from autologous and donor oocytes in Indian sub-continent: results from 2444 births [J]. Acta Obstet Gynecol Scand. 2019;98(6):715–21.
doi: 10.1111/aogs.13541
pubmed: 30663773
Scherrer U, Rimoldi SF, Rexhaj E, et al. Systemic and pulmonary vascular dysfunction in children conceived by assisted reproductive technologies [J]. Circulation. 2012;125(15):1890–6.
doi: 10.1161/CIRCULATIONAHA.111.071183
pubmed: 22434595
Dita Musalkova E, Sticova M, Reboun, et al. Variable X-chromosome inactivation and enlargement of pericentral glutamine synthetase zones in the liver of heterozygous females with OTC deficiency [J]. Virchows Arch. 2018;472(6):1029–39.
doi: 10.1007/s00428-018-2345-x
pubmed: 29623395
Yorifuji T, Muroi J, Uematsu A et al. X-inactivation pattern in the liver of a manifesting female with ornithine transcarbamylase (OTC) deficiency. Clin Genet, 54(4): 349–53.